Home » Topics » Regulatory » EMA

EMA
RSS

EMA approves centralized review of Pulmaquin

March 18, 2016

Regulatory agencies review Zydelig over serious adverse events in ongoing trials

March 16, 2016

EMA launches new PRIME program

March 7, 2016

EMA grants eligibility for submission of XBiotech's MAA for Xilonix

March 7, 2016

Baxalta submits MAA for Adynovi for the treatment of hemophilia A

March 3, 2016

FLAG-003 awarded E.U. orphan drug designation for glioma

March 2, 2016

EMA committee recommends approval of Idelvion for hemophilia B

March 2, 2016

EMA committee recommends approval of Giotrif for advanced squamous cell carcinoma of the lung

March 1, 2016

EMA committee hands down positive opinion for Viekirax + Exviera label expansion

Feb. 29, 2016

CHMP recommends approval of Taiho's Lonsurf for metastatic colorectal cancer

Feb. 29, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 2, 2026.
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
Amlogenyx’s AM-805 reduces amyloid plaques in AD
BioWorld Science
The potent carboxypeptidase enzyme protective protein cathepsin A (PPCA) is known to cleave the C-terminus of amyloid-β42, responsible for aggregation and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 31, 2026
Atai Therapeutics patents new 5-HT2 receptor agonists
BioWorld Science
Atai Therapeutics Inc. has identified new 5-HT2 receptor agonists potentially useful for the treatment of psychiatric disorders.